PL3655038T3 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number
PL3655038T3
PL3655038T3 PL18746859.0T PL18746859T PL3655038T3 PL 3655038 T3 PL3655038 T3 PL 3655038T3 PL 18746859 T PL18746859 T PL 18746859T PL 3655038 T3 PL3655038 T3 PL 3655038T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL18746859.0T
Other languages
English (en)
Inventor
Christophe ROBERGE
Anthony RECH
Jean-Manuel CROS
Myriam ABBASSI
Adolfo LÓPEZ-NORIEGA
Lea PEBREL
Audrey Petit
Juliette SERINDOUX
Original Assignee
Medincell S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell S.A. filed Critical Medincell S.A.
Publication of PL3655038T3 publication Critical patent/PL3655038T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
    • C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18746859.0T 2017-07-17 2018-07-17 Kompozycja farmaceutyczna PL3655038T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533370P 2017-07-17 2017-07-17
PCT/EP2018/069442 WO2019016236A1 (en) 2017-07-17 2018-07-17 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
PL3655038T3 true PL3655038T3 (pl) 2025-04-22

Family

ID=63047314

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18759254.8T PL3655017T3 (pl) 2017-07-17 2018-07-17 Kompozycja farmaceutyczna
PL18746859.0T PL3655038T3 (pl) 2017-07-17 2018-07-17 Kompozycja farmaceutyczna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18759254.8T PL3655017T3 (pl) 2017-07-17 2018-07-17 Kompozycja farmaceutyczna

Country Status (25)

Country Link
US (3) US11666527B2 (pl)
EP (4) EP3655017B1 (pl)
JP (3) JP7187738B2 (pl)
KR (1) KR102745079B1 (pl)
CN (1) CN111107840A (pl)
AR (3) AR113097A1 (pl)
AU (1) AU2018304881B2 (pl)
BR (1) BR112020001031A2 (pl)
CA (1) CA3069787A1 (pl)
DK (2) DK3655017T3 (pl)
EA (1) EA202090161A1 (pl)
ES (2) ES3015765T3 (pl)
FI (2) FI3655038T3 (pl)
HR (2) HRP20250087T1 (pl)
HU (2) HUE070046T2 (pl)
IL (1) IL271986B2 (pl)
LT (2) LT3655038T (pl)
MX (1) MX2020000618A (pl)
PL (2) PL3655017T3 (pl)
PT (2) PT3655017T (pl)
RS (1) RS66643B1 (pl)
SI (2) SI3655038T1 (pl)
SM (1) SMT202500130T1 (pl)
TW (3) TWI795423B (pl)
WO (3) WO2019016234A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
LT3655038T (lt) * 2017-07-17 2025-02-10 Medincell S.A. Farmacinė kompozicija
GB201900258D0 (en) 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
US11680107B2 (en) * 2019-03-22 2023-06-20 Taipei Medical University Hydrogel composition for drug delivery and uses thereof
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil
JP2023509981A (ja) * 2020-01-10 2023-03-10 エキリーブル バイオファーマシューティカルズ べスローテン フェンノートシャップ アベルメクチンによる神経障害の治療
GB202010340D0 (en) 2020-07-06 2020-08-19 Medincell Pharmaceutical composition
EP4014963A1 (en) * 2020-12-16 2022-06-22 Medincell Pharmaceutical composition
CN116847827A (zh) * 2020-12-16 2023-10-03 美蒂森股份公司 用于预防性治疗SARS-CoV-2病毒（COVID-19）的方法和组合物
GB202104224D0 (en) * 2021-03-25 2021-05-12 Medincell Pharmaceutical composition
US20240325294A1 (en) * 2021-04-30 2024-10-03 Medincell Sa Etonogestrel formulation
MX2024001681A (es) 2021-08-05 2024-03-04 Medincell S A Composicion farmaceutica.
CA3266264A1 (en) * 2023-01-10 2024-07-18 Medincell Sa OLANZAPINE COMPOSITIONS AND METHODS OF USE
AU2024381207A1 (en) 2023-11-17 2026-05-14 Institut National de la Santé et de la Recherche Médicale Antineoplastic combinations
WO2025224317A1 (en) * 2024-04-25 2025-10-30 Medincell S.A. A method for targeting pharmaceutically active principle in total knee replacement

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113359A (en) 1995-04-13 1999-06-20 Univ Ben Gurion Polysaccharide drug delivery matrix and slow release pharmaceutical preparation containing it
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
WO1999007343A1 (en) 1997-08-08 1999-02-18 University Of Utah Research Foundation Injectable biodegradable block copolymer gels for use in drug delivery
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US7018645B1 (en) * 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US20020192286A1 (en) * 2001-03-27 2002-12-19 Macromed, Incorporated Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
IL151288A0 (en) 2001-08-27 2003-04-10 Yissum Res Dev Co Multi-component reverse thermo-sensitive polymeric systems
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20030228366A1 (en) 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CA2618404A1 (en) 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
DK1996643T3 (da) * 2006-03-09 2010-06-14 Coloplast As Nedbrydelig hydrofile blokcopolymerer med forbedret biokompatibilitet til regenerering af blødt væv
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
TWI388591B (zh) 2008-03-28 2013-03-11 Ind Tech Res Inst 溫度敏感性材料
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7993666B2 (en) 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US20100015049A1 (en) 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
EP2512487A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2011079279A2 (en) 2009-12-23 2011-06-30 Board Of Trustees Of The University Of Illinois Nanoconjugates and nanoconjugate formulations
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
MY165655A (en) * 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
CN102058909A (zh) 2011-01-18 2011-05-18 复旦大学 聚乙二醇－共聚酯嵌段共聚物防粘连材料及其制备方法与应用
EP2691078A1 (en) * 2011-03-31 2014-02-05 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
ES2820369T3 (es) * 2011-03-31 2021-04-20 Ingell Tech Holding B V Composiciones biodegradables adecuadas para liberación controlada
EP2674167A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Controlled activation of complement components for use as endogenous adjuvant
KR102189442B1 (ko) * 2012-06-27 2020-12-11 메딘셀 에스.에이. 소수성 조성물용 생분해성 약물 전달
US8954932B2 (en) * 2012-12-11 2015-02-10 International Business Machines Corporation Crash notification between debuggers
AU2014252689A1 (en) 2013-04-11 2015-10-15 Commonwealth Scientific And Industrial Research Organisation Composition for controlled delivery of bioactive agents
KR101512759B1 (ko) 2013-08-30 2015-04-16 아주대학교산학협력단 이온성 작용기가 곁사슬 또는 말단에 도입된 온도감응성 폴리에틸렌글리콜/폴리에스터 블록 공중합체 및 이의 제조방법
CN103601878B (zh) 2013-11-25 2015-05-13 沈阳药科大学 高稳定性聚乙二醇-聚酯聚合物及其应用
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
EP3134083A1 (en) 2014-04-18 2017-03-01 Pfizer Inc. Nanoparticles comprising docetaxel for treating cancers having a k-ras mutation
WO2016172042A1 (en) 2015-04-18 2016-10-27 The Texas A&M University System Polymer systems and their applications in diagnostics and drug delivery
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
WO2017044936A1 (en) 2015-09-11 2017-03-16 Pfizer Inc. Methods of controlling morphology of polymeric nanoparticles
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US20170266187A1 (en) 2016-03-15 2017-09-21 Pfizer Inc. Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105878174B (zh) 2016-04-26 2021-06-29 广州帝奇医药技术有限公司 一种固体分散体及其制备方法与应用
CN105878191B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 缓释微粒的制备方法、制得的缓释微粒及其应用
CN105963257B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
DK3503877T3 (en) 2016-08-26 2022-05-23 Sk Joint Ventures Ii Llc Biodegradable polymer formulations for extended efficacy of botulinum toxin
LT3655038T (lt) * 2017-07-17 2025-02-10 Medincell S.A. Farmacinė kompozicija

Also Published As

Publication number Publication date
US11612563B2 (en) 2023-03-28
US20200163873A1 (en) 2020-05-28
CA3069787A1 (en) 2019-01-24
HRP20250339T1 (hr) 2025-05-09
RS66643B1 (sr) 2025-04-30
JP2020527590A (ja) 2020-09-10
AR113248A1 (es) 2020-03-11
TW201907956A (zh) 2019-03-01
EP3655037A1 (en) 2020-05-27
JP2020527587A (ja) 2020-09-10
EP3655038A1 (en) 2020-05-27
DK3655038T3 (da) 2025-02-17
JP7210816B2 (ja) 2023-01-24
MX2020000618A (es) 2020-09-28
EP4574906A3 (en) 2025-09-10
IL271986B2 (en) 2023-08-01
TWI795422B (zh) 2023-03-11
JP2020527586A (ja) 2020-09-10
FI3655038T3 (fi) 2025-02-11
BR112020001031A2 (pt) 2020-07-14
TW201907954A (zh) 2019-03-01
LT3655017T (lt) 2025-04-10
FI3655017T3 (fi) 2025-03-27
PT3655038T (pt) 2025-02-04
EP4574906A2 (en) 2025-06-25
JP7205019B2 (ja) 2023-01-17
KR102745079B1 (ko) 2024-12-24
WO2019016236A1 (en) 2019-01-24
SMT202500130T1 (it) 2025-05-12
AR113097A1 (es) 2020-01-29
HRP20250087T1 (hr) 2025-03-28
US20200179518A1 (en) 2020-06-11
EP3655038B1 (en) 2024-12-18
TWI795421B (zh) 2023-03-11
JP7187738B2 (ja) 2022-12-13
WO2019016234A1 (en) 2019-01-24
LT3655038T (lt) 2025-02-10
US20200171157A1 (en) 2020-06-04
PL3655017T3 (pl) 2025-06-09
US11666527B2 (en) 2023-06-06
JP7210816B6 (ja) 2023-02-03
JP7205019B6 (ja) 2023-02-03
ES3010399T3 (en) 2025-04-02
EP3655037B1 (en) 2025-01-22
CN111107840A (zh) 2020-05-05
SI3655017T1 (sl) 2025-06-30
TWI795423B (zh) 2023-03-11
PT3655017T (pt) 2025-03-26
EP3655017A1 (en) 2020-05-27
ES3015765T3 (en) 2025-05-07
AU2018304881B2 (en) 2024-06-20
IL271986B1 (en) 2023-04-01
KR20200032719A (ko) 2020-03-26
AR113096A1 (es) 2020-01-29
SI3655038T1 (sl) 2025-05-30
HUE070046T2 (hu) 2025-05-28
TW201907955A (zh) 2019-03-01
WO2019016233A1 (en) 2019-01-24
AU2018304881A1 (en) 2020-01-30
DK3655017T3 (da) 2025-03-31
EP3655017B1 (en) 2025-01-22
US11801217B2 (en) 2023-10-31
HUE070940T2 (hu) 2025-07-28
IL271986A (en) 2020-02-27
EA202090161A1 (ru) 2020-06-29

Similar Documents

Publication Publication Date Title
EP3722358A4 (en) COMPOSITION
DK3697376T3 (da) Sammensætning
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3655017T3 (da) Farmaceutisk sammensætning
EP3513809A4 (en) MEDICAL COMPOSITION
EP3493799A4 (en) CANNABIS
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
EP3493798A4 (en) CANNABIS
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
DK3634377T3 (da) Farmaceutisk formulering
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
DK3583943T3 (da) Farmaceutisk sammensætning
MA49837A (fr) Compositions pharmaceutiques
SMT202400478T1 (it) Composizione farmaceutica
DK3728220T3 (da) Farmaceutiske forbindelser
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3675653C0 (fr) Composition antimycotoxine
EP3646863A4 (en) PHARMACEUTICAL COMPOSITION
EP3524250A4 (en) PHARMACEUTICAL COMPOSITION
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
EP3646865A4 (en) DRUG
EP3616722A4 (en) PHARMACEUTICAL COMPOSITION
DK3601277T3 (da) Farmaceutisk formulering